In vitro susceptibilities of the microsporidia Encephalitozoon cuniculi, Encephalitozoon hellem, and Encephalitozoon intestinalis to albendazole and its sulfoxide and sulfone metabolites.
In vitro comparisons demonstrated that the efficacy of albendazole, albendazole-sulfoxide, and albendazole-sulfone against pathogenic Encephalitozoon species was proportional to the degree of oxidation at a concentration of >10(-3) microgram/ml. Furthermore, at a concentration of <10(-2) microgram/ml, benzimidazoles were more effective against Encephalitozoon cuniculi and Encephalitozoon hellem than against Encephalitozoon intestinalis.
Ridoux
O
O
Unité des Rickettsies CNRS UPRES-A 6020, Faculté de Médecine, Université de la Méditerranée, 13385 Marseille cedex 05, France.
Drancourt
M
M
D015766:Albendazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D016819:Encephalitozoon / Q000187:drug effects* / Q000254:growth & development; D009670:Encephalitozoon cuniculi / Q000187:drug effects* / Q000254:growth & development; D005347:Fibroblasts; D006801:Humans
D000981:Antiprotozoal Agents; C027187:albendazole sulfone; D015766:Albendazole; C027186:albendazole sulfoxide